流感、COVID-19与细菌相关ARDS的下气道微生物群组成存在差异
该研究纳入53例符合柏林定义、需有创通气的ARDS患者,其中COVID-19 24例、流感18例、细菌性CAP相关ARDS 11例,均在入院时采集气管内吸引物,扩增V3-V4和ITS2区域后深度测序。结果三组间下气道细菌群和真菌群的β多样性均不同(p=0.05和p=0.01);细菌性CAP相关ARDS组细菌α多样性显著低于COVID-19 ARDS组(p=0.04);流感相关ARDS组肺真菌α多样性高于COVID-19相关ARDS组(p=0<01)。结论提示下气道微生物群组成随ARDS病因不同而异,未来研究应把病因纳入考虑。
要点
- 53例需有创通气的柏林定义ARDS患者中,COVID-19 24例、流感18例、细菌性CAP相关ARDS 11例,入院时采集气管内吸引物测序。
- 三组间下气道细菌群β多样性不同(p=0.05),真菌群β多样性也不同(p=0.01)。
- 细菌性CAP相关ARDS组细菌α多样性显著低于COVID-19 ARDS组(p=0.04)。
- 流感相关ARDS组肺真菌α多样性高于COVID-19相关ARDS组(p=0<01)。
- 作者认为未来研究ARDS病理生理中肺微生物群作用时应考虑病因。
适用人群与场景
- 连续纳入符合柏林分类、需有创通气的ARDS患者,且PCR确诊流感或SARS-CoV-2感染,或细菌感染(气管内吸引物> 105 CFU/mL)。
诊断标准与关键阈值
- ARDS按柏林分类标准诊断。
- 细菌感染定义为气管内吸引物> 105 CFU/mL。
- 流感或SARS-CoV-2感染经PCR确诊。
研究设计与关键结果
- 研究类型为比较下气道微生物群组成的观察性研究,纳入53例需有创通气的ARDS患者:COVID-19 24例、流感18例、细菌性CAP相关ARDS 11例。
- 入院时采集气管内吸引物,扩增V3-V4和ITS2区域,MiSeq测序仪深度测序,DADA2流程分析。
- 三组间下气道细菌群β多样性不同(p=0.05),真菌群β多样性也不同(p=0.01)。
- 细菌性CAP相关ARDS组细菌α多样性显著低于COVID-19 ARDS组(p=0.04)。
- 流感相关ARDS组肺真菌α多样性高于COVID-19相关ARDS组(p=0<01)。
证据类型、等级与局限
- 证据类型:观察性比较研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来研究ARDS病理生理中肺微生物群作用时应考虑病因。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute respiratory distress syndrome (ARDS) is responsible for 400,000 deaths annually worldwide. Few improvements have been made despite five decades of research, partially because ARDS is a highly heterogeneous syndrome including various types of aetiologies. Lower airway microbiota is involved in chronic inflammatory diseases and recent data suggest that it could also play a role in ARDS. Nevertheless, whether the lower airway microbiota composition varies between the aetiologies of ARDS remain unknown. The aim of this study is to compare lower airway microbiota composition between ARDS aetiologies, i.e. pulmonary ARDS due to influenza, SARS-CoV-2 or bacterial infection.
METHODS: Consecutive ARDS patients according to Berlin's classification requiring invasive ventilation with PCR-confirmed influenza or SARS-CoV-2 infections and bacterial infections (> 105 CFU/mL on endotracheal aspirate) were included. Endotracheal aspirate was collected at admission, V3-V4 and ITS2 regions amplified by PCR, deep-sequencing performed on MiSeq sequencer (Illumina®) and data analysed using DADA2 pipeline.
RESULTS: Fifty-three patients were included, 24 COVID-19, 18 influenza, and 11 bacterial CAP-related ARDS. The lower airway bacteriobiota and mycobiota compositions (β-diversity) were dissimilar between the three groups (p = 0.05 and p = 0.01, respectively). The bacterial α-diversity was significantly lower in the bacterial CAP-related ARDS group compared to the COVID-19 ARDS group (p = 0.04). In contrast, influenza-related ARDS patients had higher lung mycobiota α-diversity than the COVID-19-related ARDS (p = 0 < 01).
CONCLUSION: Composition of lower airway microbiota (both microbiota and mycobiota) differs between influenza, COVID-19 and bacterial CAP-related ARDS. Future studies investigating the role of lung microbiota in ARDS pathophysiology should take aetiology into account.
参考来源
- Imbert S, Revers M, Enaud R, et al. Lower airway microbiota compositions differ between influenza, COVID-19 and bacteria-related acute respiratory distress syndromes. Crit Care. 2024. PMID: 38649970. doi:10.1186/s13054-024-04922-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。